Newsletter | April 22, 2024

04.22.24 -- Big Impacts In Small, Non-Profit Bios

SPONSOR

3 Solutions to the Worsening Clinical Trial Patient Travel Problem

The increase in travel distance, time, and frequency suggests travel is a bigger barrier to patient recruitment and retention than the industry previously thought. However, Elligo Health Research® offers several solutions to overcoming the patient-travel barrier.

PATIENT CENTRICITY

Big Impacts In Small, Non-Profit Bios

From The Editor | By Matthew Pillar, editor, Bioprocess Online

Debra Weiss, RN, MSN, and COO at the biopharma Gates Medical Research Institute (Gates MRI), offers a case study in creating success through service-oriented leadership.

Protocol Designs That Maximize The Value Of Hybrid Studies

Article | By Graham Wylie, MRN - Medical Research Network

Sponsors can maximize the value of hybrid clinical trials by prioritizing patient experience in trial design, balancing technologies with in-home care, site visits, and more to achieve the right design.

PATIENT RECRUITMENT

Understanding Human Behavior To Help Improve Patient Adherence

Guest Column | By Claire Everitt, Pfizer/BEAMER and Aad R. Liefveld, BEAMER

In clinical trials, early dropout rate across all conditions still hovers around 30% and almost 70% of the protocol deviations are potentially linked to non-adherence. The BEAMER project, in part, sets to remedy that.

Racial Diversity: Clinical Findings, Challenges, And The Role Of CROs

Article | OCT Clinical

Race and ethnic inclusion matter. When creating a clear picture of the safety and efficacy of a drug, uncover diversity's critical role in studies for providing clinically meaningful insights.

Ethnobridging In Phase I Clinical Trials

Webinar | Altasciences

Learn how ethnic differences can impact the bioavailability of your drug candidate and strategies for the design of your multiregional clinical development program.

CLINICAL SITES

Neurodegenerative Diseases: Trial Site Selection, Design Insights

Guest Column | A conversation with Lahar Mehta, M.D., Amylyx Pharmaceuticals

Amylyx’s head of global clinical development Lahar Mehta, M.D., talks about multistakeholder trial design, purposeful site selection, the importance of caregiver burden, and the benefits of an open-label extension (OLE).

Routes To Sponsor Of Choice: Shared Pipelines, Streamlined Payments

White Paper | IQVIA Technologies

Ensuring consistent, timely payments to clinical trial sites maintains stability and positive relationships. See how being a preferred sponsor can drive the adoption of a unified payment solution.

The Secret Sauce In Successful Clinical Trial Payments Programs

White Paper | By Jackie Torres and Jason Fanelli, IQVIA Technologies

Many clinical tech firms provide tailored software for site payments, yet they often demand significant sponsor involvement. What's the key to streamlining this process effectively?

CHOOSE YOUR OWN ADVENTURE

You're receiving the Monday edition of the Clinical Leader newsletter, focusing on Clinical Sites, Patient Centricity, and Patient Recruitment. To make changes to your newsletter selections, update your topic preferences.

  • Clinical Sites | Patient Centricity | Patient Recruitment (Monday)
  • Clinical Trial Technology (Tuesday)
  • Decentralized Trials | Trial Management (Wednesday)
  • Outsourcing Models | Regulatory & Compliance (Thursday)
  • Clinical Data Management & Analytics | Trial Monitoring (Friday)

Learn more about our personalized newsletters here.

Connect With Clinical Leader: